myocardial%20infarction%20w_%20st-segment%20elevation
MYOCARDIAL INFARCTION W/ ST-SEGMENT ELEVATION
Myocardial infarction is death of cardiac myocytes (necrosis) caused by prolonged ischemia. The term acute "usually" refers to the time 6 hours to 7 days following pathologic appearance of the infarct.
The patient may experience ischemic-type chest discomfort with accompanying symptoms of nausea, vomiting, dyspnea, diaphoresis, lightheadedness, dizziness, syncope, fatigue and weakness.
Rapid diagnosis and risk stratification of chest pain in patients are important to identify acute myocardial infarction patients who will benefit from reperfusion therapy.

Myocardial Infarction w/ ST-Segment Elevation Drug Information

Drug Information

Indication: 60 mg: Co-administered w/ acetylsalicylic acid (ASA) for prevention of atherothrombotic events in adult patien...

Indication: Substitution treatment of essential HTN &/or stable CAD in patients already controlled w/ perindopril &...

Indication: HTN. Stable CAD: Risk reduction of cardiac events in patients w/ history of MI &/or revascularisation. 5 m...

Indication: Symptomatic relief of moderate to severe pain, especially associated w/ neoplastic disease, MI & surgery. ...

Indication: Thrombolytic treatment in acute MI, acute massive pulmonary embolism w/ haemodynamic instability & of acut...

Indication: Thrombolytic treatment of acute MI. Treatment initiated as soon as possible after symptom onset.

Indication: Essential HTN. Reduction of the risk of MI, stroke or death in patients ≥55 yr at high risk developing majo...

Indication: Essential HTN when BP is inadequately controlled by monotherapy w/ telmisartan.

1  /  13
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 12 Sep 2020
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.
Audrey Abella, 16 Sep 2020
The final results of EVAPORATE* reinforce the plaque-regressing potential of icosapent ethyl (IPE) in patients on statins for elevated triglycerides.